Природные и синтетические антикоагулянты и их использование для регуляции клеточной активности
Диссертация
Проведен сравнительный анализ внутриклеточной динамики нормальных, опухолевых и трансформированных клеток в интактном состоянии и после воздействия различных факторов регуляции клеточной активности (тромбин, ЕОБ, ЮТ-а, АФП). Обнаружено, что воздействие каждого из испытанных факторов приводит к возникновению новых внутриклеточных колебаний, частоты которых частично встречаются только… Читать ещё >
Список литературы
- Александров В.А., Давыдов В. В., Беспалов В. В. и др., Эффекты и механизмы антиканцерогенного и онкопрофилактического действия препаратов растений семейства аралииевых.// Тезисы конгресса «Человек и лекарство», 1995, С. 194.
- Барбараш А.Н. Волновые процессы в живом: основы стереогенетики и физиологии мышления. Одесса, ОМ, 1998, 349 С.
- Баскова И.П. Белки системы гемостаза. В: Белки и пептиды. Т.1. — Под ред. В. Т. Иванова. — М., Наука, 1995, С.397−433.
- Баскова И.П., Халиль С., Никонов Г. И. и др. Ингибирование калликреина плазмы крови человека секретом слюнных желез и экстрактом из медицинской пиявки Hirudo medicinalis. //Биохимия, 1988, Т.53, стр. 1467−1473.
- Василенко И.А., Шабалин В. Н., Бабакова C.B., Конрадов A.A. Динамическая фазометрия как метод оценки морфофункционального состояния биообъекта// Проблемы лимфологии и количественной патологии. M., РМА, 1997, С.98−99
- Верясова Г. В. Фактор некроза опухоли: множественность биологических эффектов и методы их оценки. Оболенск, 1992, 17 С.
- Вядро М.М. Цитокины и их роль в патогенезе и терапии инфекций//Антибиотики и химиотерапия. 1990, Т.35,№ 9, С. 12−14.
- Габбасов З.А., Попов Е. Г., Гаврилов И. Ю. и др. Новый высокочувствительный метод анализа агрегации трмбоцитов// Лабораторное дело, 1989, № 10,С. 15−18.
- Галактионов В. Г. Иммунология. М.,.Изд-во МГУ. 1998, 480 С.
- Ю.Давыдов В. В., Тоскуева Е. П., Морозов В. Г. и др. Эффективность культуральных адаптогенов при различных видах вторичных иммунодефицитов//. Тезисы конгресса «Человек и лекарство», 1995, стр135.201
- П.Дубинина Л. Г., Бигалнев А. Б. Тест-система оценки мутагенной активности загрязнений среды в культуре лейкоцитов крови человека. М.: 1978, с. 107.
- Духанин А.С., Губаева Ф. Р. Фармакологическая регуляция активности тромбоцитов//Экспер.Клин. Фармак., 1998, Т.61, № 4, С.66−71
- Западнюк И.П., Западнюк В. И., Захария Е. А. Лабораторные животные. Киев, Вища школа, 1983, 384С.
- Каменев Ю.Я., Каменев О. Ю. Вам поможет пиявка.СПб., Комплект, 1997, 256С.
- Колхир В.К., Сакович Г. С., Зюзин В. А. Растительные антикоагулянты. //Тезисы конгресса «Человек и лекарство», 1995, стр.236
- Кудрявцев А.А., Кудрявцева Л. А. Клиническая гематология животных. М.: 1980 ч.2. 235С.
- Лакин Г. Ф. Биометрия. М.: Высшая школа, 1980, 293 с.
- Лихачева Н.В. Клиническая энзимология// Вопр. Биол.мед.фарм.химии., 2000, № 2, С.45−53.
- Любимов И.И., Хомяков Ю. Н., Чепурнов С. А. и др. Противоопухолевая активность некоторых сапониновых фракций корня красного женьшеня на модели мышиной меланомы В-16.// Тезисы конгресса «Человек и лекарство», 1995, стр201.
- Манишкина Р.П., Степанова Е. Б., Заугольникова Л. А. и савт. Приготовление Т+В, Т-, В-лимфоцитов для методов НЬА-типирования.//Инструкция. М., 1997,12С.202
- Меньшиков B.B. Лабораторные методы исследования в клинике. Справочник. М., Медицина, 1987. 386С.
- Методические рекомендации по оценке аллергенных свойств фармакологических средств (изд. официальное). М.: 1988.
- Методические рекомендации по проверке мутагенных свойств у новых лекарственных препаратов.М.: 1981, с. 203.
- Пальцев М.А., Иванов A.A. Межклеточные взаимодействия. М., Медицина, 1995, 224С.
- Практическая химия белка. Под ред. А.Дарбе. — М., Мир, 1989,623С.
- Савинов В.А., Кучерский В. М. Гирудотерапия в комплексном лечении больных хроническим простатитом// В: Лечение медицинскими пиявками и препаратами из них. Под ред. д.б.н. И. П. Басковой, книга 1. М., 1998, С.66−68.
- Савинов В.А., Кучерский В. М. Роль трудотерапии в профилактике рака.// Материалы третьей конференции ассоциации гирудологов. М., 1993, С.28−29.
- Сидорин Д.Н., Козюков A.B., Захарова В. А., Породенко Н. В., Крюков Л. Н. Синтез и исследование на блокаду обратного захвата серотонина амидофосфатов пиперазинилхинолинов. //Хим.-фарм. ж. 1992. Т. 26. № 9−10. С. 82−83.
- Соколов С.Я., Замотаев И. П., Справочник по лекарственным растениям, изд. 3. М. 1989 «Металлургия»
- Терентьев П.В., Ростова Н. С. Практикум по биометрии. Л.:Изд-во Ленинградского ун-та. 1977, 152 С.
- Федосеева В Н., Порядин Г. В., Ковальчук Г. В. и соавт. Руководство по иммунологическим и аллергологическим методам в гигиенических исследованиях. М., Промедэк, 1993, С. 320.
- Фукс Б.Б., Рахмилевич А. Л., Пименов А. А., Дубровская А. Г. Активация продукции фактора некроза опухоли при сочетанном действии липополисахарида и мурамилдипептида. //Бюлл. эксп. биологии и медицины. 1987,№ 10,С.497−499.
- Хомяков Ю Н. Изучение рецепторных систем органов дыхания как основа для создания новых лекарственных препаратов// М., ГНИИ ЭМП, 1999.-вып.1, 26С., вып.2, 24С.
- Хомяков Ю.Н., Василенко И. А., Конрадов А. А., Гусев В. В. Прижизненная экспресс-оценка действия новых биопрепаратов: использование компьютерной лазерной микроскопии// Сб.науч.тр. ВГНКИ.-1996.-Т.59, — С. 121−126.
- Хомяков Ю.Н., Федоров Т. В., Борисов Н. В. и соавт. Препарат из медицинских пиявок ингибирует развитие саркомы сирийского хомяка// Асклепейон 1995. N1−4, С.28−30.
- Чабан Т.Н., Капралова В. В., Савинов В. А. Гирудотерапия в гинекологической практике.// В: Лечение медицинскими пиявками и препаратами из них. Под ред. д.б.н. И. П. Басковой, книга 1. М., 1998, С. 68.
- Abraham L.A., Jenkins A.L., Stone S R. et al. Expression of the thrombin receptor in developing bone and associated tissues// J. Bone Miner. Research., 1998 V.13, P.818−827.
- Aderka D., Engelman H., Maor Y. et all. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.//! Exp. Med. 1992, V.175, P.323−331.
- Aggarwal B.B., Eesalu Т.Е., Hass P.E. Characterization of receptors for human tumor necrosis factor and their regulation by gamma interferon.//Nature.l985,V.318, P.665−667.
- Ahn H., Arik L., Boykow G. et al. Structure-activity relationships of pyrrolquinazolines as thrombin receptor antagonists//Biorg. Med. Chem. Lett., 1999, V.9, P.2073−2078.
- Ahn H.S., Arik L., Boykow G. .et all. Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists // Bio.Med. Chem.Lett., 1999, V. 9P.2073−2078.
- Amar S., Van Dyke T.E., Eugster H.P. et all, Tumor necrosis factor (TNF)-induced cutaneous necrosis is mediated by TNF-receptor 1. //J.Inflamm, 1996, V.47, P. 180−189.
- Antman E.M. for the TIMI 9A Investigators: Hirudine in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. // Circulation, 1994, V.90, P. 1624−1630.
- Ault K.A., Tawfik O.W., Smith-King M M. et all, Tumor necrosis factor-alpha response to infection with Chlamidia trachomatis in human tube organ culture. I I Am. J. Obstet. Gynecol., 1996, V.175, P. 1242−1245.
- Bagdy D., Barabas E., Szell E. et all, In vitro inhibition of blood coagulation by tripeptide aldehydes- a retrospective screening study focused on the stable D-mePHE-Pro-Pro-Arg-HH2 S04. // Thromb. Haemost. ! 992, V.67, P.325−330
- Bajust S., Barabas E., Szell E. et all, Peptide aldehhyde -inhibitors of the fibrinogen -thrombin reaction./" Meienhofer J (Ed) //Peptides -Chemistry, Structure and Biology. Ann Arbor Science Publishers, 1975, P.603−608.
- Bajust S., Barabas E., Tolnay P. et all, Inhibition of thrombin and trypsin by tripeptide aldehydes, // Int.J. Pept. Protein. Res, 1978, V.12, P.217−221
- Bajust S., Szell E., Bagdy D. et all, US Patent No.4, 703,036,1987
- Balkwill F.R. Tumor necrosis factor// Brit. Med. Bul.-1989, V.45, N.2, P.389−400.205
- Ball R.L., Albrecht T., Thompson W. et al. Thrombin, epidermal growth factor, and phorbol myristate acetate stimulate tubulin polimerization in quiescent cells: a potential link to mitogenesis// Cell Motil. Cytoskeletion, 1992, V.23, P.265−278.
- Barabas E., Szell E., Bajusz S., Screening for fibrinolysis inhibitory effect of synthetic thrombin inhibitors, //Blood Coagul. Fibrinolysis, 1993, V.4, P. 243−248
- Bar-Shavit R., Kahn A., Wilner G. et al. Monocyte chemotaxis: stimulation by specific exocyte region in thrombin// Science, 1983, V.220,P.728−731.
- Baxevanis C. N, Spanacos G., Voutsas I.F. et all Increased generation of autologous tumor- reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha.// Cancer Immunol. Immunother., 1999.V.48, P.71−84.
- Bendtzen K. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity.// Immunology Letters. 1988, V. 19, P. 183−192.
- Benezra M., Vlodavsky I., Bar-Shavit R. Thrombin enchances degradation of heparan sulfate in the extracellular matrix by tumor cell heparanase// Exp. Cell Res., 1992, V.201, P.208−215.
- Berger D.P., Naniche D., Crowley M.T. Lymfotoxine-beta -deficient mice show defective antiviral immunity. // Virology, 1999, V.260, P. 136−147.
- Bock L.C., Griffin L.C., Latham J.A. et all, Selection of single-stranded DNA molecules that bind and inhibit human thrombin. // Nature, 1992, V.355, P.564−566.
- Bonavida B. Role of NKCF and TNF in cell-mediated cytotoxicity. // Lymphokine Receptor Interaction. 1989 V.179., P.99−105.
- Bowie A.G., Moynagh P.N., O'Neill L.A.J., Lipid peroxidation is involved in activation of NF-kappa B by tumor necrosis factor but not interleukin-1 in the human endothelian cell line ECV304.//J.Biol. Chem., V.272, P.25 941−25 950.
- Brewer G. Exogenous thrombin inhibits neuritogenesis in cultured neuroblastoma cells but not in hippocampal neurons/ZBrain Res., 1995, V.683, P.258−263.
- Browning G., Ribolini A., Studies of the differing of tumor necrosis factor and lymphotoxin on the growth of several human tumor lines.// J.Immunol.1989, V.143, N.6, P.1859−1867
- Browning J.L., Douglas I, Ngamek A. et all, Characterization of surface lymfotoxin forms. //J. Immunol., 1995, V.154, P.33−46.
- Browning J.L., Miatkowski K., Sizing I., et all, Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. // J. Exp. Med., 1996, V. 183, P.857−878.
- Buijsman R.C., Basten J.E.M., van Dither T.G. et all, Design and synthesis of a novel synthetic NAPAP-penta-saccharide conjugate displaying a dual antithrombotic action. // Bio.Med. Chem.Lett., 1999, V.9, P.2013−2018.
- Busing K. Pseudomonas hirudinis ein bakterieller Darmsymbiont des Blutegels (Hirudo officinalis) //Zentr. Bakt. Parasit. Infekt.Hyg., 1952, V.157, P.478−484.
- Bussolino F., Arese M., Montrucchio G. et al. Platelet activating factor produced in vitro by Kaposi’s sarcoma cells induces and sustains in vivo angiogenesis.// J. Clin Invest., 1995, V.96, P.940−952.
- Callas D., Bacher P., Iqbal O et all, Fibrinolytic compromises by simultaneous administration of site-directed inhibitors of thrombin. // Thromb. Res., 1994, V. 74, P. 193 205
- Callas D., Fareed J., Comparative anticoagulant effects of various thrombin inhibitors as determined in the ecarin clotting method. // Thromb. Res. 1996, V.83, P.463−468
- Calnek D.S., Grinnel B.W. Thrombomodullin-dependent anticoagulant activity is regulated by vascular endothelial growth factor// Exp. Cell Res., 1998, V.238, P.294−298.
- Cannone C.P.Maraganore J.M. Loscalzo J. Anticoagulant effects of hirulog, a novel thrombin inhibitor. //Am J. Cardiol., 1993, V.71, P.778−782.
- Carrell R.W. How serpins are shaping up// Science, 1999, V.285, P. 1861−1863.
- Carter A., Haddad N., Draxler I. et all, Expression and role in growth regulation of tumor necrosis factor-receptors p55 and p75 in acute myeloblastic leukemia cells.// Br.J. Haematol., 1996, V.92, P. 116−126
- Castellino A.M., Chao M.V. Trans-signalling by cytokine and growth factor receptors// Cytokine Growth Factor Rev., 1996, V.7, P.297−302.
- Castellino A.M., Parker G.J., Boronenko I.V. et all, A novel interaction between the juxtamembrane region of the p55 tumor necrosis factor receptor and PIP5K. // J. Biol. Chem., 1997, V.272, P.5861−5870.
- Castor C.W., Smith E.M., Bignal M.C., Hosier P.A., 1997Connective tissue activation. XXVII. Effects of cytokine combination, implications for an integrated cytokine network.
- Castro J.M., Barcia M.G. Localization of prothymosin alpha in the nucleus. // Biochem. Biophys. Res. Commun., 1996, V.224, P. 140−146.
- Chambard J.C., Paris S., L’Allemain G. et al. Two growth factor signalling pathways in fibroblasts distinguished by pertussis toxin// Nature, 1987, V.326, P. 800−803.208
- Chaplin D.D. Cytokine regulation of secondary lymphoid organ development. // Curr. Opin. Immunol. 1998, V.10, P.289−297.
- Chen L.B., Buchanan J.M. Mitogenic activity of blood component. 1. Thrombin and prothrombin//PNAS, 1975, V.72, P.131−135.
- Chen L.B., Buchanan J.M. Mitogenic activity of blood components. 1. Thrombin and prothrombin//PNAS, 1999, V.72, P.131−135.
- Cheng L., Scully M.F., Goodwin C.A. et all, Peptide a-aminophosphonic acids: A new type of thrombin inhibitor. // Thromb. Haemost., 1991, V.65,P.1289.
- Chiang H.S., Swaim M.W., Huang T.F. Characterization of platelet aggregation induced by human colon adenocarcinoma cells and its inhibition by snake venom peptides, trigramin and rhodostomin// Br.J.Haematol., 1994, V.87,P.325−331.
- Chiang H.S., Yang R.S., Huang T.F. The Arg-Gly-Asp-containing peptide, rhodostomin, inhibitsin vitro cell adhesion to extracellular matrices and platelet aggregation caused by Saos-2 human osteosarcoma cells// Br.J.Cancer, 1995, V.71,P.265−270
- Choay J. Native antithrombin III, an activable protein. Hin Doutremepuich C. (ed.) Anticoagulation. 1994, 119−133.
- Choi S.S., Gatanaga M., Granger G.A.et all, Prostaglandin e-2 regulation of tumor necrosis factor receptors release in human monocytic THP-1 cells.// Cell Immunol., 1996, V.170, P. 178−184.
- Clauss M., Grell M., Fangmann C et all, Synergistic induction of endotelian tissue factor by tumor necrosis factor: functional analysis of the tumor necrosis factor receptors. //FEBS Lett. V.390, P.334−338
- Clerici M., Sarin A., Berzofsky J.A. et all, Antigen-stimulated apoptotic T-cell death in HIV infection is selective for CD4+ T cells, modulated by cytokines and effected by lymphotoxin. //AIDS, 1996, V.10,P.603−611.
- Colleman R.W., Activation of plasminogen by human plasma kallikrein // Biochem Biophys. Res. Commun. 1968, V.38, P. 346−388
- Collen D., Lijnen H.R. Todd P. A. et all, Tissue type plasminogen activator: A review of its pharmacology and therapeutic use as a thrombolytic agent. // Drugs 1989, V.38P. 346 388.
- Concise encyclopedia of biochemistry,-Berlin, New York, Walter de Gryter, 1983,460P.
- Conway E.M., Pollefeyt S., Collen D. et al. The amino terminal lectin-like domain of thrombomodullinis required for constitutive endocytosis//Blood, 1997, V.89, P.652−661.
- Cuff C. A., Schwartz J., Bergman C.M. et all. Lymfotoxin alpha3 induces chemokines and adhesion molecules: insight into the role of LT alpha in inflammation and lymphoid organ development.//J. Immunol., 1998, V.161,P.6853−6860.
- Dabbous M.K., North S.M., Haney L. et all, Effects of mast cell-macrophage interaction on the production of collagenolytic enzymes by metastatic tumor cells and tumor-derived and stromal fibroblasts.// Clin. Exp. Metastasis, 1995, V.13, P.33−41.
- Daub H., Weiss F.U., Wallasch C., Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors//Nature, 1996, V.379, P.557−560.
- De Fouw N.J., van Hinsberk V.W., de Jog Y.F. et all. The interaction of activated protein C and trombin with the plasminogen activator inhibitor released from human endotelian cells // Thromb. Haemost., 1987, V57, P176.210
- De Kossodo S., Moore R, Gschmeissner S. et all, Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumor necrosis. // Br. J. Cancer, 1995, V.72, P. 1165−1172.
- DeBlois D., Drapeu G., Petitclerc E. et al. Synergysm between the contractile effect of epidermal growth factor and that of des-Arg9-bradikinin or alpha-thrombinin rabbit aortic rings//Br. J.Pharmacol., 1992, V.105, P.959−967.
- Denisov A.A., Nicolaeva O.G., Investigation of biosynthesis of human lymphotoxinin cells of recombinant Escherichia coli strain. // Biotechnol. Appl. Biochem., 1998, V.28, P. 19−23.
- Desser L. Cytokine synthesis in human periferal blood mononuclear cells after oral administration ofpolyenzyme preparations// Oncology, 1993, V.33, P.753−762
- Dhanasekaran N., Tsim S., Dermott J. et al. Regulation of cell proliferation by G proteins//Oncogene, 1998, V. 17, P. 13 83−1394.
- Dichek D., Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator-1 in cultured human umbilical vein endothelial cells // Blood, 1989 V.74, P.222−228.
- Dinarello C.A., The biology of interleukin-1 and comparison to tumor necrosis factor.//Immunology Letters 1987, V.16, P.227−232.
- Dodt J., Kohler S., Schmitz T. et all, Distinct binding sitcs of Ala 48-hirudin 1−47 and Ala 48-hirudin 48−65 on thrombin. // J. Biol. Chem., 1990, V.265, P.713−718.
- Douni E., Kollias G. A critical role of the tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. // J. Exp. Med., 1998, V.188, p. 1343−1352.
- Doutremepuich C., LalanneM. C, Doutremepuich F. et all, Low molecular weight heparins today./'". Doutremepuich C. (Ed). Dekker M Low Molecular Weight Heparins in Clinical Practice, N-Y, 1992, P.85−96.
- Duchaussoy P., Jaurand G., Driguez P. A et all, Assessment through chemical synthesis of the size of the heparin sequence involved in thrombin inhibition. // Carb. Res., 1999, V.317, P.85−99.
- Duchaussoy P., Jaurand G., Driguez P. A et all, Identification of a hexasaccharide sequence able to inhibit thrombin and suitable for 'polymerization'. // Carb. Res., 1999, V.317, P.63−84
- Duhamel C., Orvain C., Lanza F. et al. Thrombin receptor-mediated increase of two matrix metaloproteinases, MMP-1 and MMP-3, in human endothelial cells// Arteroscl.Thromb.Vasc.Biol., 1997, V.17, P.1931−1938.
- Dutton G. Anti-angiogenesis for cancer. //Genetic Engineering news, 1999, V. 19, P. l-28.
- Dutton G. Anti-angiogenesis for cancer// Gen. Eng. News, 1999, V. 19, № 17, October 1, P. 1,28,46.
- Eidt J.F., Allison P., Nobel S. et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury// J.Clin. Invest., 1989, V.84,P. 18−27.
- Eldor A., Orevi M., Rigbi M. The role of the leech in medical therapeutics. // Blood Rev., 1996, Y.10, P.201−209.
- Enkemann S.A., Pavur K.S., Ryazaniv A G., Does prothymosine alpha affect the phosphorylation of elongation factor 2? // J. Biol. Chem., 1999, V.274, P. 18 644−18 650.
- Ensumi N., Fan D., Filder I.J. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor// Cancer res., 1991, V.51, P.4549−4556.
- Eriksson B.I., Ekman S., Kalebo P. t all, Prevention of deep-vein thrombosis after total hip replacement. // Lancet, 1996, V.347, P. 635−639.
- Ernst E., Matrai A. Orale herapie mit proteolytishen Enzymen modifiziert die Blutrheologie//Klin.Wschr., 1987, V.65, P.994−996.
- Ettinger R., Mebius R., Browning J.L. et all, Effects of tumor necrosis factor and lymphotoxin on peripheral lymphoid tissue development. // Int. Immunol. 1998, V.10, P.727−741.
- Even-Ram S., Uziely B., Cohen P. et al. Thrombin receptor overexpression in malignant and physiological processes// Nature Medicine, 1998, V.4, P.909−914.
- Fajaro L.F., Kwan H.H., Kowalsky J., Prionas S.D., Allison A.C. Dual role of tumor necrosis factor-alpha in angiogenesis// Am. J. Pathol., 1992, V.140, P.539−547.
- Fareed J., Callas D., Hoppensteadt D. et all, Recent development in antithrombotic agents. Exp. Opin. Drugs, 1995, V.4, P. 389−412.
- Fareed J., Mesmore H.L. Kindel G. et all, Inhibition of serine proteases by low molecular weight peptides and their derivatives//NY Acad. Sei., 1981, V.370, P.765−784
- Fareed J. Current trends in antithrombotic drug device development in Doutremepuich C. (ed.) Anticoagulation. 1994, 1−37.
- Fareed J. Hoppensteadt D.A., Walenga J.M. et all., Antithrombin agents as anticoagulants and antithrombotics. //Med. Clin. ofNA, 1998, V.82., P.569−572.
- Feugeas J.P., Caillns H., Poirier J.C. et all, Influence of metabolic and genetic factors on tumor necrosis factor-alpha and lymphotoxin -alpha in insulin-dependent diabetes mellitus. //Diabetes Metab., 1997, V.1997, P.295−301.
- Flynn J.L., Goldstein M.M., Chan J. et all, Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. // Immunity, 1995, V.2, P.561−572.
- Force W.R., Walter B.N., Hession C. et all, Mouse lymphotoxin beta receptor. Molecular genetic, ligand binding, and expression. //. J. Immunol., 1995, V.155,P.5280−5288.
- Fu Y.X., Huang G., Wang Y. et all. B- lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha dependent fashion. // J. Exp. Med., 1998, V. 187, P. 1009−1018.
- Gallea Robach S., Morand V., Millet S et all, A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells.// Cytokine V.9, P.340−346.
- Garbin F., Eckert K., Immenschuh P. et all, Prothymosin alpha 1 effects, in vitro, on the antitumor activuty and cytokine production of blood monocytes from colorectal tumor patients.// Int. J. Immunol., 1997, V.19, P.323−332.
- Gasic G. Thrombin inhibitors promote metastasis// Periodicum Biologorum, 1991, V.93, P.633−640.
- Geiger J. Anti-aggregatory drugs: 1. Platelet receptor antagonists//Exp.Opin.Ther.Patents, 1999, V.9, P. 1389−1414.
- Geiger J. Anti-aggregatory drugs: I. Platelet receptor antagonists. // Exp. Opin. Ther. Patents, 1999, V.9, P. 1389−1414
- Gerszten R., Chen J., Ishil M. et al. Specifity of the thrombin receptor for agonist peptide is defined by its extracellular surface// Nature, 1994, V.368, P.648−651.214
- Gertz S.D., Fallon J.T., Gallo R. et al. Hirudin reduces tissue factor expression in neotima after balloon injury in rabbit femoral and porcine coronary arteries// Circulation, 1998, V.98, P.580−587.
- Gibbs C.S., Coutre S.E., Tsiang M. et all. Conversion of thrombin into an anticoagulant by protein engineering. //Nature, 1995, V.378, P.413−416.
- Gillboa N., Villanueva M.T., Fenton J.W.II., Inhibition of fibrinolytic enzymes by thrombin inhibitors. //Enzyme, 1988, V.40, P.144−148.
- Goldsmith G.H., Saito O.D., Ratnoff O.D., The activation of plasminogen by Hageman factor fragments. // J.Clin.Invest.1978, V.62, p.54−60.
- Grande J.P., Melder DC, Zinsmeister A R., Modulation of collagen gene expression by cytokines. //J. Lab. Clin. Med., 1997, V.130, P.476−486.
- Grottesi A., Sette M., Palamara T. The conformation of peptide thymosin alpha 1 in sodium and in a membrane-like environment by circular dichroism and NMR spectroscopy.//Peptides, 1998, V.19,P.1731−1738.
- Gruss H.J. Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. // Int. J. Clin. Lab. Res., 1996, V.26, P.143−159.
- Hall C.S. Emotional behavior in the rat. J. Physiol, Phsychol., 1934, v. 18, p.385−403.
- Haralabopoulos G.C., Grant D.S., Kleinman H.K. et al. Thrombin promotes endothelial cell alignment in matrigelin vitro and angiogenesis in vivo//Am.J.Physiol., 1997, V.273(lPtl), C.239−245.
- Harker L/A/ Therapeutic inhibition of thrombin activities, receptors and production, // in: Ellis J. Nuffield (ed.) Hematology/Oncology clinics of North America/ Coagulation Disorders and Treatment Strategies, 1999.
- Hattori R, Hamilton K., Fugati R. et al. Stimulated secretion of endotelial vWF is accompanied by rapidredistribution to the cell surface of the intracellular membrane protein GMP-140// J.Biol.Chem., 1989, V.264, P.7768−7771.
- Herbert J., Guy A., Lamarche I. et al. Intimal hyperplasia following vascular injury is not inhibited by an antisense thrombin receptor oligodeoxynucleotide.//J.Cell Physiol., 1997, V.170, P.106−114.
- Hermann J R., Kutryk M.J., Serruys P.W., Clinical trial of direct thrombin inhibitors during invasive procedures.// Thromb. Haemost., 1997, V.78, P.367−376.
- Hernandez M., Bayon Y., Sanches C. et al. Thrombin produces phosphorilation of cytosolic phospholipase A2 by a mitogen-activated protein kinase-independent mechanism in the human astrocytoma cell line 1321Nl//Biochem.J., 1997, V.328, P.263−269.
- Hijikata-Okunomiya A., Okamoto S. A strategy for a rational approach to designing synthetic selective inhibitors. // Semin. Thromb. Haemost., 1992, V18, P. 135−149.
- Hildt E., Oess S., Identification of Grb2 as a novel binding partner of tumor necrosis factor (TNF) receptor 1. // J. Exp. Med., 1999, V.189, P. 1707−1714.
- Hooper J. A., McDaniel M.C., Thurman G. B. et all, Purification and properties of bovine thymosine.// Ann. N.Y. Acad. Sc., 1975, V.249, P. 125−144.
- Hunt J.S., Chen H.L., Miller L. Tumor necrosis factors: pivotal components of pregnancy? //Biol.Reprod., 1996, V.54, P.554−562
- Iizuca K., Chaplin D.D., Wang Y. et all, Recruitment. For membrane lymphotoxin in natural killer cell development.// Proc. Nati. Acad. Sci. USA, 1999, V.96, P.6336−6340.
- Ijzerman G.N., Marquet R.L., Interferon -gamma. //A Review Immunobiology. 1989, V. 179, P.456−473.
- Imamura K., Springgs D., Kufe D. Expression of tumor necrosis factor receptors on human monocytes and internalization of receptor bound ligand.// J. Immunology, 1987, V. 139, P.2989−2992.
- Iredat P.A., Dickenson J. M. Measurement of intracellular free calcium ion concentration in cell population using Fura-2// In.: Signal transduction protocols, Ed. by D.A. Kendal, 1995, V.41, P.203−215.
- Ishihara H., Connoly A., Zeng D. et al. Protease-activated recepor-3 is a second thrombin receptor in humans// Nature, 1997, V.386, P.502−506.
- Ito D., Back T.C., Shakhov AN. et all, Mice with targeted mutation in lymphotoxin -alpha exhibit enhanced tumor growth and metastasis: impaired NK cell development and recruitment. //J. Immunol. 1999, V.163, P.2809−2815.
- Jennings J., Van der Lander M. Histochemical and bacteriological studies on digestion in nine species of leeches// Biol.Bull., 1967, V.133, P.166−183.
- Jennings J.B. and Van Der Lande V. Histochemical and bacteriological studies on digestion in nine species of leeches (Annelida: Hirudinea)// Biol.Bull., 1967, V.133, № 1, P.166−182.
- Kahn M., Zheng Y, Huang W. et al. A dual thrombin receptor system for platelet activation//Nature, 1998, V.394, P.690−694.
- Kerth S., Fisslthaler B., Busse R. serotonin stimulates the expression of thrombin receptors in cultured vascular smooth muscle cells. Role of protein kinase C and protein tyrosine kinases// Circulation, 1996, V.93, P.2170−2177.
- Kettner C., Mesinger L., Knabb R. The selective inhibition of thrombin by peptides of boroarginine. //J. Biol. Chem, 1990, V.265, P. 18 289−18 297.
- Kettner C., Shaw E., The selective inhibition of thrombin by peptides of chloromethylketone. // In Lundblad R.L.et all (Ed): Chemistry and Biology of Thrombin., Ann Arbor Science Publishers, 1993, P. 129−144
- Kim H.H., Lee D.E., Shin J.N.et all, Receptor activator of NF-kappaB recruits multiply TRAF family adaptors and activates c-Jun N-terminal kinase.// FEBS Lett., 1999, V.443, P.297−302.
- Kinnard Karr. A preliminatory procedure for the evaluat of CNS depressant. J.Pharmacol. Exp. Therapeur, 1957, v. 121, p.354.
- Knauer M.F., Hawley S.B., Knauer D.J. Identification of binding site in protease nexin (PN1) required for the receptor mediated internalization of PNl-thrombin complexes//J. Biol. Chem., 1997, V.272, P. 12 261−12 264.
- Knobe K.E., Berntsdotter A., Shen L. et al. Probing the activation of protein C by the thrombin-thrombomodullin complex using structural analysis, site-directed mutagenesis, and computer modelling// Proteins, 1999, V.35, P.218−234.218
- Ko Y., Totzke G., Gouni-Bertold I. et all, Cytokine inducible growth factor gene expression in human umbilical endotelial cells. // Mol. Cell Probes, V. 13, P.203−211.
- Kobayashi H., Fucata J., Murakami N. et all, Tumor necrosis factor receptors in the pituitary cells. // Brain Res., 1997, V.758, P.45−50.
- Kohame K., Zheng X., Sadler J. Activation of thrombin-activable fibrinolisis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulinand is inhibited competitively by protein C//J.Biol.Chem., 1998, V.273, P. 12 135−12 139.
- Korner H., Cook M., Riminton D.S., Distinct roles for lymphotoxin -alpha lymphotoxin -alpha and tumor necrosis factor in organogenesis and spatial organization on lymphoid tissue. //Eur. J. Immunol. 1997, V.27, P.2600−2609.
- Kost E R, Mutch D.G., Herzog T.J., Interferon-gamma and tumor necrosis factor-alpha induce synergic cytolitic effects in ovarian cancer cell lines-roles of the TR60 and TR80 tumor necrosis factor receptors. // Gynecol. Oncol., 1999, V.72, P.392−401.
- Kost E.R., Herzog T.J., Adler L.M. et all, The role of tumor necrosis factor receptor in tumor necrosis factor-alpha-mediated cytolysis of ovarian cancer cell lines.//Am.J.Obstet.Gynecol.V.174, P. 145−153.
- Kramer R.M., Roberts E.F., Hyslop P.A. et al. Differential activation of cytosolic phospholipase A2 (cPL A2) by thrombin and thrombin receptor agonist peptide in human platelets//J.Biol.Chem., 1995, V.270, P.14 816−14 823.
- Kronke M., Schutze S., Scheurich P. et all. Tumor necrosis factor signal transduction //Cell. Signal-ling, 1990, V.2,P.l-8.
- Kulmburg P., Radke M., Digel W. Lymphotoxin alpha is an autocrine growth factor for chronic lymphocytic leukemia B cells // Leukemia, 1998, V.12, P.493−498.
- Lecompte T.H. Kher A., Gaillard J.L. et all, Pharmaccologie des agents antiplaguettaires. //J.desMal. Vasculaires. 1983, v.8, P.3−5219
- Leist M., Gantner F., Bohlinger I et all, Tumor necrosis factor -induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. // Amer. J. Pathol., 1995, V.146, P.1220−1234.
- Leo E., Welsh K., Matsuzawa S. et all, Differential requirement for tumor necrosis factor receptor associated factor family proteins in CD40 — mediated induction of NF-kB and Jun
- Lewis C.E., Leek R, Harris A., et all, Cytokine regulation of angiogenesis in breast cancer: the role of tumor associated macrophages.// J. Leukoc. Biol., 1995, V.57, P.747−751.
- Li M., Lin Z., Johnson M.E., Structure-based design and synthesis of novel thrombin inhibitors based on phosphinic peptide mimetics. // Bioorg and Med. Chem. Lett., 1999, V.9, P. 1957−1962.
- Li M., Zhaolan L., Johnson M. Structure-based design and synthesis of novel thrombin inhibitors based on phosphinic peptide mimetics// Biorg. Med. Chem. Lett., 1999, V.9, P. 1957−1962.
- Li W.X., Kaplan A.V., Grant G.W. et all. A novel nucleotide-based thrombin inhibitor inhibits clot- bound thrombin and reduced arterial platelet thrombus formation. // Blood, 1994, V.83, P.677−682.
- Li Y.Q., Hii C.S., Costabile M., Regulation of lymphotoxin production by the p21ras-raf-MEK-ERK cascade in PHA/PMA-stimulated Jurkat cells. // J. Immunol. 1999, V.162, P. 3316−3320.
- Li Z.R., Hromchak R., Mudipalli A., Bloch A., Tumor suppressor proteins as regulators of cell differentiation.// Cancer Res., 1998, V.58, P.4287−4285.
- Liu L.S., Spelleken M., Rohrig K. et all, Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytec: implication of the p80 tumor necrosis factor receptor.// Diabetes, 1998, V.47, P.515−522.
- Loewy A., Santer U., Wieczorek M. et al. Purification and characterization of a novel Zinc-proteinase from cultures of Aeromonas hydrofila. J. Biol. Chem., 1993, V.268, P.9071−9078.
- Loidi L, Vidal A., Zalvide J.B. et all, Development of ELISA to estimate thymosine alpha 1, the N terminus of prothymosin alpha, in human tumors. // Clin. Chem., 1997, V.43, P.59−63.
- Loidi L., Garcha Caballlero T., Vidal A. et all, Complex regulation of prothymosin alpha in mammary tumors arising in transgenic mice. // Life Sci. 1999, V. 64, P. 21 252 133.
- Lu C., Giordano F., Bao X. et al. Antisense fosB RNA inhibits thrombin-induced hypertrophy in cultured pulmonary arterial smooth muscle cells// Circulation, 1998, V.98, P.596−603.
- Ludke E.S., Humes G.L. Effect of tumor necrosis factor on granule release and LTB4 production in adherent human polymorphonuclear leukocytes. //Agents and actions. 1989, V.27, N.3−4, P.451−454.
- Macaya R.F., Schultze P. Smith F.W. et all., Thrombin-binding DNA aptamer forms a unimolecular quardruplex structure in solution. // Proc. Natl.Acad. Sci. USA, 1993, V. 90, P. 3745−3749.
- Mackay F., Browning J.L., Lawton P. et all. Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. // Gastroenterology, 1998, V. 115, P. 1464−1475.
- Mao S.J., Yates M.T., Owen T.J. et all, Interaction of hirudin with thrombin // Biochemistry, 1988, V.27, P.8170−8173.
- Maragarone J.M., Bourdon P., Jablonski J. et all, Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. // Biochemistry, 1990, V.29, P.7095−7101.
- Mardiguian J. Methods of preparation of low molecular weight heparins in Doutremepuich C. (Ed). Dekker M. Low Molecular Weight Heparins in Clinical Practice, N-Y, 1992, P. 7−12.
- Mari B., Guerin S., Far D.F. et al. Thrombin and trypsin-induced Ca2+ mobilization in human T-cell lines through interaction with different protease-activated receptors// FASEB J., 1996, V.10, P. 309−316.
- Markwardt F. Coagulation inhibitors from blood-sucking animals. // Pharmazie, 1994, V.49, P.313−316.
- Marshall W.L., Brinkman B.M., Ambrose C.M. et all. Signaling through the lymfotoxin beta receptor stimulates HIV- 1 replication alone and in cooperation with soluble or membrane — bound TNF-alpha. // J. Immunol. 1999, V. 162, P.6016−6023.
- Maruyama I., Synthetic anticoagulants. // Jpn J. Clin. Hematol., 1990, V.31, P.776−781.
- Matsumoto M., Fu Y.X., Molina H. Distinct roles of lymphotoxin alpha and the type 1 tumor necrosis factor (TNF) receptor in the establishment of follicular dendritic cells from non-bone marrow-derived cells. // J. Exp. Med., 1997, V.186, P.1997−2004.
- Matsuo T., Kario K., Kodama K. et all., Clinical application of the synthetic thrombin inhibitor, Argatroban (MD-805). // Semin. Thromb. Haemost., 1992, V18, P. 155−160.222
- McCusker R H., Clemmons D.R. Effects of cytokines on insuline-like growth factor-binding protein secretion by muscle cells in vitro// Endocrinology, 1994, V.134, P.2095−2102.
- Meager A., Leung H., Woolley G. Assays for tumor necrosis factor and related cytokines.//1989, V. 116, P. 1−17.
- Mentz S., de Lacale S., Baerga O.A. et al. Mechanism of thrombin clearance by human astrocytoma cells//J.Neurochem., 1999, V.72, P.980−987.
- Mentz S., de Lacalle S., Baerga O. et al. Mechanism of thrombin clearence by human astrocytoma cells// J.Neurochem., 1999, V.72, P.980−987.
- Merlo G.R., Basolo F., Fiore L. Et all, p53-dependent activation of apoptosis in mammary epithelial cells reveals a curvival function of EGF and insulin.// J. Cell. Biol., 1995, V. 128, P. 1185−1196.
- Molino M., Bainton D., Hoxie J. et al. Thrombin receptor on human platalets// J.Biol.Chem., 1997, V.272,P.6011−6017.
- Morimoto A., Sakata Y., Watanabe T. et all, Characteristics of fever and acute phase response induced in rabbits by IL-1 and TNF //Amer. J. of Physiol. 1989, V.256, N. l, P. R41-R35.
- Morris D.L., Ward J.B. Jr., Nechay P. et al. Highly purified human alpha-thrombin promotes morphological transformation of Balb/c 3T3 cells// Carcinogenesis, 1992, V.13, P. 1−7.
- Mossman T. Rapid colorimetric assay for cellular growth and cytotoxicity assays// J. immunol. meth., 1983.V.65, P.55−63.
- Muhle R., Green D., Moore M.A. et al. Constitutive production and thrombin-induced of vascular endothelial growth factor by human megakaryocytes and platelets// PNAS, 1997, V.94, P.663−668.
- Murphy M., Walter B.N., Pike-Nobile L. et all, Expression of the lymphotoxiln beta receptor on follicular stromal cells in human lymphoid tissues.// Cell Death Differ., 1998, V.5, P.497−505
- Nagata S., Golstein P., The Fas death factor.//Science, 1995, V, 267, P.1449−1456.
- Natoli G., Costanzo A., Moretti F. Et all, Tumor necrosis factor (TNF) receptor 1 signaling downstream of TNF receptor-associated factor2.// J. Biol. Chem., V.272, P.26 079−26 082.
- Naylor P.H., Smith M.R., Mutchnik M.G. et all, Thymosin alphal does not promote growth or oncogenic transformation. // Int. J. Immunopharmacol., 1996, V. 18, P.321−327.
- Neises B., Tarnus C., Thrombin inhibition by the tripeptide trifluoroomethyl ketone D-Phe-Pro-Arg-CF3 (MDL73756).//Thromb. Haemost., 1991, V.65,P.1290.
- Nierodzik M L., Plotkin A., Kajumo F., Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo// J.Clin.Invest., 1991, V.87, P.229−236.
- N-terminal kinase activation.// J. Biol. Chem., 1999, V.274, P.22 414−22 422.
- Ohshima Y., Yang L.P., Avice M.N. Naive human CD4+ cells are a major source of lymfotoxin alpha. //J. Immunol., 1999, V. 162, P.3790−3794.
- Or R., Kalinkovich A., Nagler A. et all, Soluble tumor necrosis factor (sTNF) receptors: a possible prognostic marker for bone marrow transplantation-related complications.// Cytokines Mol. Ther., 1996, V.2, P.243−250.
- Oshiro T., Kanbayashi J., Kosaki G. Antithrombotic therapy of patient with peripheral arterial reconstruction-clinical study on MD805. // Blood Vessel, 1983, V. 14, P.216−218.
- Osoba D., Miller J. The lymphoid tissues and immune responses of neonatally thymectomized mice bearing thymus tissues in millipore diffusion chambers.// J. Exp. Med., 1964, V. 119, P. 177−194.
- Owen L.B., Shaub W.L., Crump, Morin G.I. et all. Regulation of lymphocyte tumor necrosis factor receptors by IL-2.//J.of Immunology. 1989 V.143,N.7P.2236−2241.
- Paborsky L.R., McCurdy S.N., Griffin L.C. et all. The single-stranded DNA aptamer binding-site of human thrombin. // J. Biol. Chem. 1993, V.268, P.20 808.
- Park Y.C., Burkitt V., Villa A.R.et all, Structural basis for self-association and receptor recognition of human TRAF2. //Nature, 1999, V.398, P.533−538.
- Pendurthi U., Williams J.T., Rao L.V. Acidic and basic fibroblast growth factors supress transcriptional activation of tissue factor and other inflammatory genes in endothelial cells//Arteroscl.Thromb.Vasc.Biol., 1997, V. 17, P.940−946.
- Pica F., Fraschetti C., Matteucci C. High doses of thymosin alpha 1 enhance the antitumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. // Anticancer Res., 1998, V.18, P.3571−3578.
- Plummer J.S., Berryman K.A., Cai C. et al. Potent and selective bicyclic lactam inhibitors of thrombin: part 3. PI 'modifications// Biorg. Med. Chem. Lett., 1999, V.9., P.835−840.
- Plummer J.S., Berryman K.A., Cai C. et all, Potent and selective bicyclic lactam inhibitors of thrombin: part 3: PI’modifications. // Bio.Med. Chem.Lett., 1999, V.9P.835−840.
- Pober J.S.Cotran R.S., Cytokines and endotelian cell biology/ZPhysiol.Rev. 1990, V.70, P.427−451.
- Poller W., Wilnow T.E., Hilpert J. et al. Differential recognition of alpha-1-antitrypsin-elastse and alpha-1-antichymotrypsin-cathepsin G complexes by the low densitylipoprotein receptor-related protein// J.Biol.Chem., 1995, V.270,P.2841−2845.
- Pozo D., Guerrero J.M., Sagura J.J. et all, Thymosin alphal interacts with the VIP receptor-effector system in rat and mouse immunocompetent cells. // Immunopharmacology, 1996, V.34, P. 113−123.
- Rao G., Runge M. Cyclic AMP inhibition of thrombin-induced growth in vascular smooth muscle cells correlates with decreased JNK1 activity and c-Jun expression// J.Biol.Chem., 1996, V.271, P.20 805−20 810.
- Rapuano B.E., Bockman R.S., Protein kinases A and C positively regulate G protein -dependent activation of phosphatidylinositol-speciflf phospholipase C by tumor necrosis factor-a in MC3T3-E1 osteoblasts. //J. Cell. Biochem. 1997, V.65, P. 198−208.
- Reiner J., Lim-Wilby M., Brunck T. et al. Investigation of the S3 site of thrombin- design, synthesis and biological activity of 4-substituted 3-amino-2-pyridones incorporating Pl-argininals//Biorg. Med. Chem. Lett., 1999, V.9, P.895−900.
- Reiner J.E., Lim-Wilby M.S., Brunck T.K. et all, Investigation of the S3-site of thrombin: design, synthesis and biological activity of 4-substituted 3-amino-2-pyridones incorporating Pi- argininals. //Bio.Med. Chem.Lett., 1999, V.9, P.895−900.
- Rodrigues P., Vicuela J.E., Alvarez Fernandes L. et all, Overexpression of prothymosin alpha accelerates proliferation and retards differentiation in HL-60 cells. // BiochemJ., 1998, V.331, P.753−761.
- Rothe M., Sarma V., Dixit V.M., et all, TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. // Science, 1995, V.269, P. 1424−1427.
- Rubtsov Y.P., Zolotukhin A.S., Vorobjev I.A. et all, Mutational analisis of human prothymosin alpha reveals a bipartite nuclear localization signal.// FEBS Lett., 1997, V.413, P. 135−141.226
- Ryuto M., Ono M., Izumi H. et all, Induction of vascular endothelial growth factor by tumor necrosis factor-a in human glioma cells. Possible role of SP-1.// J. Biol. Chem., 1996, V. 271, P.28 220−28 228.
- Sancho-Tello M., Marcinkiewicz J.L., Justice W.M., Reduction of tumor necrosis factor-alpha bioactivity by a human ovarian epithelial cancer cell line in vitro. // Amer.J.Obstet.Gynecol., 1995, V. 173, P. 1470−1477.
- Scharf M., Engels J., Tripier D., Primary structures of new «isohirudins». //FEBS Lett. 1989, V.225, P. 105−110
- Schaufberg H., Nowak G., Kaufman R. Thrombin has a bimodal effect on glioma cell growth//Br.J. Cancer, 1997, V.76, P.1592−1595.
- Schutze S., Machleidt T., Adam D. et all, Inhibition of receptor internalization by monodansylcadaverin selectively blocks p55 tumor necrosis factor receptor death domain signaling. //J. Biol. Chem., 1999, V.274, P. 10 203−10 212.
- Shaker A.M. Antiplatelet therapies: from aspirin to GPIIb/IHa-receptor antagonists and beyond // DDT, 1999, V.4, P.552−561.
- Shapiro M.J., Trejo J., Zeng D. et al. Role of the thrombin receptor’s cytoplasmic tail in intrcellular trafficing// J. Biol. Chem., 1996, V.271, P.32 874−32 880.
- Shea T. Inhibition of neuronal surface proteases decreases the requirement for GAP-43 in neurite outgrowth//Brain Res.Dev.BrainRes., 1995, V.87, P.87−90.
- Shea T., Beerman M., Nixon R. Multiple proteases regulate neurite outgrowth in NB2a/dl neuroblastoma cells//J.Neurochem., 1991, V.56, P.842−851.
- Sheen-Chen S.M., Chen W.J., Eng H.L., et all. Serum concentration of tumor necrosis factors in patients with breast cancer. // Breast Cancer Res. Treat., V.43,P.211−215.
- Shi C.S., Leonardi A., Kyriakis J. TNF-mediated activation of the stress-activated protein kinase pathway: TNF receptor-associated factor 2 recruits and activates germinal center kinase related. //?Immunol., 1999, V.163, P.3279−3285.
- Shi C.S., Leonardi A., Kyriakis J. TNF-mediated activation of the stress-activated protein kinase pathway: TNF receptor-associated factor 2 recruits and activates germinal center kinase related. //J.Immunol., 1999, V.163, P.3279−3285.
- Shuman M.A. Thrombin-cellular interactions// Ann. NY Acad.Sci., 1986, V.485,P.349−368.
- Simonitsch I., Krupitza G., Autocrine self-elimination of cultured ovarian cancer cells by tumor necrosis factor-a (TNF-a). //Br. J. Cancer, 1998, V.1998, P.862−870.
- Slon-Usakiewicz J. J., Sivaraman J. Yunge L. et all, Design of PI' and P3' residues of trivalent thrombin inhibitors and their crystal structures. //Biochem., 2000, V.39,P.2384−2391.
- Smith 1., Smith J. Regulation of sodium-calcium exchanger by glucocorticoids and growth factors in vascular smooth muscle//J.Biol.Chem., 1994, V.269,P.27 527−27 531.
- Smith R.A., Baglioni C. The active form of tumor necrosis factor is a trimer//J.Biol.Chem.-1987, V.262, N.15, P.6951−6954.
- Spies T., Morton C., Nedospasov S. et all, Genes for the necrosis factor are linked to the human major histocompatibility complex. //Proc. Nation. Acad. Sc. USA, 1986, V.83, N.22, P.8699−8702.
- Stefanini G.F., Foschi F.G., Castelli E. et all, Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. //Hepatogastroenterology, 1998, V.45, P.209−215.
- Stenflo J. Contributions of Gla and EGF-like domains to the function of vitamin k-dependent coagulation factors// Critical Reviews in Euc. Gene Expression, 1999, V.9, P.59−88.
- Stewart AG., Tomlinson PR., Fernandes D.J. et al. Tumor necrosis factor alpha modulates mitogenic responses of human cultured airway smooth muscle// Am.J.Respir.Cell Mol.Biol., 1995, V.12, P.110−119.
- Stoufer G.A., Runge M.S. The role of secondary growth factor production in thrombin-induced proliferation of vascular smooth muscle cells// Semin.Thromb. Hemost., 1998, V.24, P. 145−150.
- Swaim M.W., Chiang H.S., HuangT.F. Characterization of platelet aggregation induced by PC-3 human prostate adenocarcinoma cells and inhibited by snake venom peptides, trigramin and rhodostomin// Eur.J.Cancer, 1996, V.32A, P.715−721.
- Swart A.C.W., van den Hende-Timmer E.J., van Bekkum D.W., Analysis of hormone preparation from normal and irradiated calf thymus and control preparation by sodium dodecyl sulfate electrophoresis. // Kooker Sc. Pub., Rotterdam, 1975, P.203−207.
- Takahashi N., Udagawa N., Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. // Biochem Biophys. Res. Commun., 1999, V.256, P.449−452.
- Takuwa N., Takuwa Y. Ras activity late in Gl phase required for p27kipl downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts// Mol Cell Biol., 1997, V.17, P.5348−5358.
- Tamao Y., Yamamoto T., Hirata T. et all, Effect of argipidine (MD-805) on blood coagulation //Jpn. Pharmacol. Ther., 1986, V. 14, P.869−874.
- Tamao Y., Yamamoto T., Kimumoto R., et all, Effect of a selective thrombin-inhibitor MCI-9038 on fibrinolysis in vitro and in vivo.// Thromb. Haemost., 1986, V.562, P.28−34.
- Tao L., Wang R. H., Enkemann S.A., Metabolic regulation of protein-bound glutamyl-phosphates: insights into the function of protnymosin alpha.// J. Cell Physiol., 1999, V.178, P.154−163.
- Tapparelli C., Metternich R., Ehhrhardt C et all, In vitro and in vivo characterization of a neutral boron -containing thrombin-inhibitor. // J. Biol. Chem, 1993, V.268, P.4734−4744.
- Taylor D.S., Cheng X., Pawlowski J.E. et al. Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1 and thrombin // PN AS, 1999, V.96, P.1633−1638.
- Terinzagelegging 7 904 723 Nederland (1980). / Farmacologisch werkzame 2-(l-piperazinyl)-chinolinederivaten. (Int Cl3.: C 07 D 401/04, A 61 K 31/50). 16 P.
- Tewari M., Dixit V.M. Recent advances in tumor necrosis factor and CD40 signaling. // Curr. Opin. Genet. Dev., V.6, P.39−44
- Tolkatchev D., Ni F. Calcium binding properties of an epidermal growth factor-like domain from human thrombomodullin// Biochemistry, 1998, V.37, P.9091−9100.
- Tordai A., Fenton J.W., Andersen T. et al. Functional thrombin receptor on human T lymphoblastoid cells// J.Immunol., 1993, V.150, P.4876−4886.
- Tracey K.J., Lowry S.F., Cerami A. Cachektin /TNF-a in septic adult respiratory distresses syndrom. // Amer. Rev. Resp.Dis. 1988, V. 138, N.6, P. 1377−1379.
- Tracey K.J., Vlassare H., Cerami A., Cachektin / tumor necrosis factor//Lancet., 1989, N.8647, P. 1122−1125.
- Tsitsilonis O.E., Bekris I.F., Voutsas I F. et all. The prognostic value of alpha-thymosins in breast-cancer. // Anticancer Res., 1998, V.18, P. 1501−1508.
- Vaingankar S.M., Martins G.M. Thrombin activation of the 9E3/CEF4 chemokine involves tyrosine kinases including c-src and the epidermal growth factor receptor// J.Biol.Chem., 1998, V.273, P.5226−5234.
- Verstraaete M., Direct thrombin-inhibitors: Appraisal of the antithrombotic / hemorrhagic balance. // Thromb. Haemost., 1997, V.78, P.357−363.
- Vito R., Guido A., Massimo G. et all. Comparative study on the antiviral activity of tumor necrosis factor (TNF-a), lymfotoxin (TNF-(3) and IL-1 in WISH cells.//Immunol. 1989, V.21, N.2, P. 165−169
- Vlasuk G., Vallar P.L., Weinhouse M.L., A novel inhibitor of thrombin containing multiple recognition sequences linked by a-keto amide transition state. // Circulation, 1994, V.90.P. 1−348.
- Voelkel Jonson C., Entingh A. J., Wold W.S. et all, Activation intracellular proteases in a early event in TNF-induced apoptosis. // J. Immunol., 1995, V.154, P. 1707−1716.231
- Von Albertini M., Ferran C., Brostjan C. Membrane-associated lymphotoxin on natural killer cells activates endothelial cells via NF-kappaB-dependent pathway. // Transplantation, 1998, V.66, P. 1211−1219.
- Vu T.-K., Hung D., Wheaton V. et al. Molecular cloning of a functional thrombin receptor revealsa novel proteolytic mechanism of receptor activation// Cell, 1991, V.64, P. 1057−1068.
- Wajant H., Grell M., Scheurich P. TNF receptor associated factors in cytokine signaling. // Cytokine GrowthFactor Rev., 1999, V.10, P.15−26.
- Wallach D., Varfolomeev E.E., Malinin N.L. et all, Tumor necrosis factor receptor and Fas signaling mechanisms.// Annu. Rev.Immunol., 1999, V.17, P.331−367.
- Waltz D.A., Fenton J.W. The role of thrombin in tumor cell metastasis// Invasion Metastasis, 1994, V.14, P.303−308.
- Warzocha K. JBienvenu J., Coiffier B. et all, Mechanism of action of the tumor necrosis factor and lymphotoxin ligand- receptor system. // Eur. Cytokine Netw., 1995, V.6, P.83−96.
- Webber E.M., Bruix J., Pierce R. H .et all, Tumor necrosis factor primers hepatocytes for DNA replication in the rat. // Hepatology, 1998, V.28, P. 1226−1234.
- White H.D. Clinical trials of direct thrombin-inhibitors in acute ischaemic syndromes.// Thromb. Haemost., 1997, V.78, P.364−366.
- Williams R.O., Ghrayeb J., Feldmann M. et all, Successful therapy of collagen-induced arthritis with TNF-receptor-IgG fusion protein and combination with anti-CD4. // Immunology, 1995, V. 84, P.433−439.
- Wingbield P., Roger H., Craig S., Tumor necrosis factor is a compact trimer// FEBS Letters.-1987, V.211,N. 2, P. 179−184.
- Wojtukiewicz M., Tang D., Ben-Josef E. et al. Solid tumor cells express functional «tethered ligand» thrombin receptor// Cancer Research, 1995, V.55, P.698−704.
- Wolf M., Zimper K. Die Sorgie for den Krebspatienten in der Genesendenfursorge und in der praxis vom Standpunkt des Krankerhauses// Mutteil, Osterr. Sanitatsv., 1974, V.75, P. 109−112
- Wong B.R., Josien R., Lee S.Y., et all, The TRAF family of signal transducers mediates NF-kappaB activation by TRANCE receptor.// Biol.Chem., 1998, V.273, P.28 355−28 359.
- Wood S., Holyoke D., Yardley J. Mechanism of metastasis production of blood-borne cancer cells// Canad. cancer. Conf., 1961, V.4, P. 167−223.
- Wu C.G., Boers W., Reitsima P.R. et all Overexpression of prothymosin alpha, concomitant with c-myc, during rat hepatic carcinogenesis. // Biochem. Biophys. Res. Commun., 1997, V.232, P.817−821.
- Wu C.L., Shiau A.L., Lin C.S., Prothymosin alpha promotes cell proliferation in N1H3T3 cells. // Life Sc., 1997, V.61, P.2091−2101.
- Wu M.Y., Wang P.Y., Han S.H.et all, The cytoplasmatic domain of the lymphotoxin-beta receptor mediates cell death in HeLa cells.// J. Biol. Chem., 1999, V.274, P. 1 186 811 873.
- Wu Q., Wang Y., Wang J. et all. The requirement of membrane lymfotoxin for the presence of dendritic cells in lymphoid tissues. // J. Exp. Med., 1999, V.190, P.629−638.
- Yamada M., Tanimoto A., Ichinowatari G et all, Possible participation of intracellular platelet- activating factor in tumor necrosis factor-alpha production by rat peritoneal macrophages.//Euro. J. Pharmacol, V.347, P.341−350.
- Yamada M., Tanimoto A., Ichinowatari G et all, Possible participation of intracellular platelet- activating factor in tumor necrosis factor-alpha production by rat peritoneal macrophages.//Euro. J. Pharmacol., V.347, P.341−350.
- Yan W., Tiruppathi C., Lum H. et al. Protein kinase C beta regulates heterologous desensitisation of thrombinreceptor (PAR-1) in endothelial cells// Am.J.Physiol., 1998, V.274 (2 Pt 1), C.387−395.
- Yasuhito A., Masazumi M., Teiri S., Shigeru K. Enzyme linked immunisorbent assay (ELISA) for human tumor necrosis factor (h TNF).// Clin.Chem.Acta. 1988, V.176, N.2, P.213−217.
- You L.R., Chen C.M., Lee Y.H.W. Hepatitis C virus core protein enhances NF-kappa signal pathway triggering by lymphotoxin-beta receptor ligand and tumor necrosis factor alpha.
- Zawilska K., Zozulinska M., Turowiecka Z. et all, The effect of a long- acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIC) in rabbits. //Thromb. Res., 1993, V.69, P.315−320.
- Zinetti M., Agyekum S., Evans T. et all. The role of lipopolysacharide, proinflammatory cytokines and bacterial superantigenes in the transcriptional regulation of lymphotoxin alpha and beta in mouse splenocytes. // Cytokine, 1998, V. 10, P.940−947.
- Zucker S., Conner C., DiMassmo B.I. et al. Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiological regulation of angiogenesis// J.Biol.Chem., 1995, V.270, P.23 730−23 738.